SUMAVEL DOSEPRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SUMAVEL DOSEPRO (SUMAVEL DOSEPRO).
Sumatriptan is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
| Metabolism | Primarily metabolized by monoamine oxidase A (MAO-A) to an inactive indole acetic acid metabolite; minor metabolism by CYP450 isoenzymes. |
| Excretion | Primarily renal (60% unchanged, 20% as indole acetic acid metabolite) and fecal (about 10%). Biliary excretion contributes minimally. |
| Half-life | Terminal elimination half-life is 2.5–3 hours. Clinical context: Short half-life allows titrated dosing; may prolong in hepatic impairment. |
| Protein binding | 14–21% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | 2.7 L/kg, indicating extensive tissue distribution (crosses blood-brain barrier). |
| Bioavailability | Subcutaneous: 97%; intranasal: 17%; oral: 15% (due to first-pass metabolism). |
| Onset of Action | Subcutaneous: 10–30 minutes; intranasal: 15–30 minutes; oral: 30–60 minutes. |
| Duration of Action | Lasts 2–4 hours after single dose. Clinical note: Rebound headache may occur if used frequently. |
Sumavel DosePro (sumatriptan injection) is administered subcutaneously via a single-use needle-free injector. The typical adult dose is 6 mg subcutaneously once, with a maximum of 6 mg per 24 hours. A second injection may be given at least 1 hour after the first if symptoms recur, but not more than two injections in 24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment is required for renal impairment, as sumatriptan is minimally renally eliminated. However, use with caution in patients with severe renal impairment (eGFR <15 mL/min) due to limited data. |
| Liver impairment | Sumatriptan is contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate hepatic impairment (Child-Pugh class A or B), no dose adjustment is recommended, but caution is advised due to increased exposure. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established; therefore, Sumavel DosePro is not recommended for use in children and adolescents. |
| Geriatric use | Elderly patients (≥65 years) may have increased risk of adverse events. The recommended dose is 6 mg subcutaneously once, with caution due to potential for decreased hepatic function and concomitant conditions. No specific dose reduction is mandated, but clinical monitoring is advised. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SUMAVEL DOSEPRO (SUMAVEL DOSEPRO).
| Breastfeeding | Sumatriptan is excreted in human milk with an M/P ratio of approximately 4.6 after subcutaneous administration. Peak milk concentration occurs 1–2 hours post-dose; relative infant dose is about 3.5% of maternal weight-adjusted dose. Breastfeeding should be avoided for at least 12 hours after Sumavel DosePro use; pump and discard milk during this interval. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryolethality and increased incidence of fetal abnormalities at doses ≥5 mg/kg/day (maternal toxic doses). Second trimester: No specific risks identified beyond general maternal adaptation. Third trimester: Potential risk of uterine hypertonus and reduced placental blood flow leading to fetal hypoxia, especially with parenteral administration; use only if benefit outweighs risk. |
■ FDA Black Box Warning
Do not administer Sumavel DosePro to patients with history of coronary artery disease, cerebrovascular disease, peripheral vascular disease, or uncontrolled hypertension due to risk of myocardial ischemia, infarction, and stroke.
| Serious Effects |
["Ischemic heart disease (angina pectoris, history of myocardial infarction, silent ischemia)","Cerebrovascular syndromes (stroke, transient ischemic attacks)","Peripheral vascular disease","Uncontrolled hypertension","Within 24 hours of ergotamine derivatives or other 5-HT1 agonists","Within 24 hours of MAO-A inhibitors","Severe hepatic impairment"]
| Precautions | ["Risk of myocardial ischemia, infarction, and Prinzmetal's angina","Risk of cerebrovascular events including stroke","Risk of serotonin syndrome especially with SSRIs/SNRIs","Risk of medication overuse headache","Serious cardiac arrhythmias including ventricular tachycardia"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate during administration. Assess fetal heart rate if used near term due to risk of uterine hypertonus. No routine fetal monitoring required outside third trimester. |
| Fertility Effects | No specific studies on human fertility. Animal studies show no impairment of fertility at doses up to 50 mg/kg/day subcutaneously. Reversible effects on spermatogenesis in rats at high doses; clinical relevance unknown. |